ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR
(Thomson Reuters ONE) -
GHENT, Belgium, 17 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced that Hilde Windels will be nominated as an Independent Non-
Executive Director at the Company's forthcoming Special General Meeting of its
shareholders to be held on 18 August 2017.
Mrs. Windels is currently CEO ad interim of Biocartis NV and a member of the
Board of Biocartis NV, Biocartis Group NV, Erytech Pharma SA and Vlaams
Instituut voor Biotechnologie (VIB). She has approximately 20 years of
experience in the biotechnology field with a track record of building and
structuring organisations, private fundraising, M&A, capital markets and
business and corporate strategy. Mrs. Windels served as CFO for Biocartis NV
from 2011 until she became Deputy CEO in 2015. From 2009 to 2011, she worked as
an independent CFO for several private biotech companies. From 1999 to 2008,
Mrs. Windels was CFO and a board member of Devgen NV.
Welcoming Mrs. Windels to the Ablynx Board, Dr Peter Fellner, Chairman, said:
"We are very pleased with the proposed forthcoming appointment of Hilde Windels
to the Ablynx Board. Hilde's broad industry experience as well as her impressive
financial expertise will help guide the Company as we continue to build value in
terms of both our proprietary product pipeline and strategic collaborations with
pharmaceutical companies using our Nanobody platform."
Commenting on her appointment, Mrs. Windels added: "I am delighted to become
part of Ablynx's Board and contribute to the Company's future development.
Ablynx has ambitions to become a vertically integrated pharmaceutical company
and I look forward to contributing to this exciting journey."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.,
Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx(at)fticonsulting.com
pdf version of press release:
http://hugin.info/137912/R/2120360/807783.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.07.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 552502
Anzahl Zeichen: 4044
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
